| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/22/2022 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 05/20/2021 | 4916.72% | Baird | → $9 | Initiates Coverage On | → Outperform |
| 02/18/2021 | 3244.48% | Jefferies | → $6 | Initiates Coverage On | → Buy |
| 01/04/2021 | — | William Blair | Upgrades | Market Perform → Outperform | |
| 10/08/2020 | 3244.48% | Aegis Capital | → $6 | Initiates Coverage On | → Buy |
| 08/28/2019 | — | William Blair | Initiates Coverage On | → Outperform | |
| 07/22/2019 | 290.19% | Chardan Capital | $22 → $0.7 | Downgrades | Buy → Neutral |
| 06/27/2018 | 3244.48% | Maxim Group | → $6 | Initiates Coverage On | → Buy |
| 05/24/2018 | 3244.48% | Oppenheimer | → $6 | Initiates Coverage On | → Outperform |
VistaGen Therapeutics Questions & Answers
The latest price target for VistaGen Therapeutics (NASDAQ: VTGN) was reported by William Blair on July 22, 2022. The analyst firm set a price target for $0.00 expecting VTGN to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for VistaGen Therapeutics (NASDAQ: VTGN) was provided by William Blair, and VistaGen Therapeutics downgraded their market perform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of VistaGen Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for VistaGen Therapeutics was filed on July 22, 2022 so you should expect the next rating to be made available sometime around July 22, 2023.
While ratings are subjective and will change, the latest VistaGen Therapeutics (VTGN) rating was a downgraded with a price target of $0.00 to $0.00. The current price VistaGen Therapeutics (VTGN) is trading at is $0.18, which is out of the analyst's predicted range.